The global lipid nanoparticles market size was estimated to be USD 0.892 billion in 2023 and is expected to reach at USD 4.09 billion by 2034 with a CAGR of 14.85% during the forecast period 2024-2034. Increasing demand for advanced gene delivery systems, rising focus on the development of LNP-based drugs, growing prevalence of chronic diseases, surge in demand for personalized medicines, increasing mergers & acquisition within market players, growing research & development activities by market players, and rising launch of advanced lipid products by major market players are some of the key factors boosting the market growth.
Rising launch of advanced lipid products by major market players is predicted to boost the market growth during the forecast period. Lipid nanoparticles represent highly developed gene delivery systems in clinical applications. They are typically employed for transporting nucleic acids, making them a promising choice for numerous therapeutic possibilities within the pharmaceutical field. Numerous pharmaceutical and biotech firms are prioritizing the production of drugs based on lipid nanoparticles to transport diverse therapeutic agents. For instance, In September 2022, The National Institute of Allergy and Infectious Diseases has granted a contract worth USD 13.8 million to the University of California to carry out immune profiling of lipid nanoparticles, with the aim of investigating their impact on enhancing protective responses to vaccines.
By type, solid lipids nanoparticles (SLNs) was the highest revenue-grossing segment in the global lipid nanoparticles market in 2023 owing to increasing demand for cancer treatment & drug discovery and rising number of clinical trials. Additionally, Nanostructured lipid carriers (NLCs) is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities and rising introduction advanced nanostructured lipid carriers-based drugs by market players. For instance, in April 2022, IOI Oleo GmbH developed nano lipid carriers encapsulating Azithromycin (AM) for the intention of delivering it to the eyes. These carriers were then transformed into a gel system that was evaluated for various aspects such as tissue pathology, moisture content, passage through barriers, controlled drug discharge, potential for irritation, and effectiveness against bacteria.
By application, therapeutics was the highest revenue-grossing segment in the global lipid nanoparticles market in 2023 owing to rising prevalence of chronic diseases, increasing focus on manufacturing drugs for the treatment of chronic diseases, and surge in collaborations within private & government bodies. For instance, in June 2022, Evonik AG has established a collaborative venture with the United States government to construct a state-of-the-art production facility focused on lipid-based technologies for the production of mRNA-based products. The U.S. government has allocated funding of up to USD 150.0 million for this facility through the Biomedical Advanced Research and Development Authority (BARDA). Additionally, research is predicted to grow at fastest CAGR during the forecast period owing to the surge in research & development activities, growing number of clinical trials, and increasing focus on development of LNP-mRNA-based vaccines.
By end-user, pharmaceutical & biotechnology companies was the highest revenue-grossing segment in the global lipid nanoparticles market in 2023 owing to growing demand for LNPs by market players, rising launch of novel products by pharmaceutical & biotechnology companies, and increasing collaborations within market players. For instance, in July 2022, Precision NanoSystems has partnered with Replicate Bioscience to produce genomic medications for the treatment of inflammatory and autoimmune conditions, as well as various other diseases. Additionally, research institutes is predicted to grow at fastest CAGR during the forecast period owing to the surge in research studies on LNPs for the development of innovative products and increasing introduction of advanced products.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of leading market players, rising focus on expansion by market players, and increasing focus on expansion by market players. For instance, in May 2022, Gattefosse has inaugurated a recently constructed manufacturing plant in Texas, United States, dedicated to the production of specialized lipid-based ingredients tailored for use in the pharmaceutical and cosmetic sectors. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in product approvals, growing research & development activities, rising collaborations within market players, and rising collaborations within market players for the supply of nanoparticles. For instance, in July 2023, Cytiva, a prominent player in the life sciences industry on a global scale, has introduced the NanoAssemblr commercial formulation system, specifically designed for the clinical and commercial production of medicines utilizing lipid nanoparticles.
Rising launch of advanced lipid products by major market players is predicted to boost the market growth during the forecast period. Lipid nanoparticles represent highly developed gene delivery systems in clinical applications. They are typically employed for transporting nucleic acids, making them a promising choice for numerous therapeutic possibilities within the pharmaceutical field. Numerous pharmaceutical and biotech firms are prioritizing the production of drugs based on lipid nanoparticles to transport diverse therapeutic agents. For instance, In September 2022, The National Institute of Allergy and Infectious Diseases has granted a contract worth USD 13.8 million to the University of California to carry out immune profiling of lipid nanoparticles, with the aim of investigating their impact on enhancing protective responses to vaccines.
By type, solid lipids nanoparticles (SLNs) was the highest revenue-grossing segment in the global lipid nanoparticles market in 2023 owing to increasing demand for cancer treatment & drug discovery and rising number of clinical trials. Additionally, Nanostructured lipid carriers (NLCs) is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities and rising introduction advanced nanostructured lipid carriers-based drugs by market players. For instance, in April 2022, IOI Oleo GmbH developed nano lipid carriers encapsulating Azithromycin (AM) for the intention of delivering it to the eyes. These carriers were then transformed into a gel system that was evaluated for various aspects such as tissue pathology, moisture content, passage through barriers, controlled drug discharge, potential for irritation, and effectiveness against bacteria.
By application, therapeutics was the highest revenue-grossing segment in the global lipid nanoparticles market in 2023 owing to rising prevalence of chronic diseases, increasing focus on manufacturing drugs for the treatment of chronic diseases, and surge in collaborations within private & government bodies. For instance, in June 2022, Evonik AG has established a collaborative venture with the United States government to construct a state-of-the-art production facility focused on lipid-based technologies for the production of mRNA-based products. The U.S. government has allocated funding of up to USD 150.0 million for this facility through the Biomedical Advanced Research and Development Authority (BARDA). Additionally, research is predicted to grow at fastest CAGR during the forecast period owing to the surge in research & development activities, growing number of clinical trials, and increasing focus on development of LNP-mRNA-based vaccines.
By end-user, pharmaceutical & biotechnology companies was the highest revenue-grossing segment in the global lipid nanoparticles market in 2023 owing to growing demand for LNPs by market players, rising launch of novel products by pharmaceutical & biotechnology companies, and increasing collaborations within market players. For instance, in July 2022, Precision NanoSystems has partnered with Replicate Bioscience to produce genomic medications for the treatment of inflammatory and autoimmune conditions, as well as various other diseases. Additionally, research institutes is predicted to grow at fastest CAGR during the forecast period owing to the surge in research studies on LNPs for the development of innovative products and increasing introduction of advanced products.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of leading market players, rising focus on expansion by market players, and increasing focus on expansion by market players. For instance, in May 2022, Gattefosse has inaugurated a recently constructed manufacturing plant in Texas, United States, dedicated to the production of specialized lipid-based ingredients tailored for use in the pharmaceutical and cosmetic sectors. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in product approvals, growing research & development activities, rising collaborations within market players, and rising collaborations within market players for the supply of nanoparticles. For instance, in July 2023, Cytiva, a prominent player in the life sciences industry on a global scale, has introduced the NanoAssemblr commercial formulation system, specifically designed for the clinical and commercial production of medicines utilizing lipid nanoparticles.
Segmentation: Lipid Nanoparticles Market Report 2022 - 2033
Lipid Nanoparticles Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Nanostructured Lipid Carriers (NLCs)
- Solid Lipids Nanoparticles (SLNs)
- Others
Lipid Nanoparticles Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Research
- Therapeutics
Lipid Nanoparticles Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Research Institutes
- Pharmaceutical & Biotechnology Companies
- Others
Lipid Nanoparticles Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Lipid Nanoparticles Market: Type Estimates & Trend Analysis
8. Lipid Nanoparticles Market: Application Estimates & Trend Analysis
9. Lipid Nanoparticles Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Lipid Nanoparticles Market
12. Europe Global Lipid Nanoparticles Market
13. Asia Pacific Global Lipid Nanoparticles Market
14. Latin America Global Lipid Nanoparticles Market
15. MEA Global Lipid Nanoparticles Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Gattefosse
- IOI Oleo GmbH
- Merck KGaA
- Evonik Industries AG
- VAV Lifesciences
- Precision NanoSystems
- Polypeptide Therapeutic Solutions (PTS)
- Danaher Corporation
- Moderna Inc
- Adium Pharma S.A.
- Croda International Plc
- Avanti Polar Lipids
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.89 Billion |
| Forecasted Market Value ( USD | $ 4.09 Billion |
| Compound Annual Growth Rate | 14.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
